OT mobile menu

Search form


Lung Cancer Targets

Study Identifies How Lung Tumors Acquire Immunotherapy Resistance

NSCLC can acquire resistance to immune checkpoint blockade agents through evolutionary culling of tumor clones harboring the mutations for cell surface neoantigens that are recognized by patients’ immune T cells. Image © Tashatuvango/ Shutterstock.com

Image © koya979 / Shutterstock.com

Lung Cancer Targets

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Dr. Heather Wakelee discusses the management of lung cancer patients who have early or delayed progression while being treated with an immune checkpoint inhibitor.

We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.

We spoke with Dr. Julie Brahmer about how survival rates are starting to improve with the use of nivolumab in non-small cell lung cancer.

The FDA on March 30, 2017, granted full approval to osimertinib for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC.

Quantitative morphological features of tumor pathological images may help predict prognosis in patients with non-small cell lung cancer.

ERBB2/HER2 mutations appear to be rare but targetable oncogenic drivers in non-small cell lung cancer, according to findings from a small retrospective cohort records analysis.


Subscribe to Lung Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.